慢阻肺痰液嗜酸性粒细胞与血嗜酸性粒细胞的关系及吸入PDE4抑制的影响
该研究探讨COPD患者痰液嗜酸性粒细胞与血嗜酸性粒细胞的关系,以及吸入PDE4抑制剂对痰液嗜酸性粒细胞的影响。证据表明PDE4抑制可降低痰液嗜酸性粒细胞较高患者的痰液嗜酸性粒细胞,支持PDE4抑制剂对嗜酸性炎症的作用。
要点
- PDE4抑制可降低痰液嗜酸性粒细胞较高COPD患者的痰液嗜酸性粒细胞。
- 血嗜酸性粒细胞较高的COPD患者对ICS临床反应更佳。
- 口服PDE4抑制剂罗氟司特在血嗜酸性粒细胞较高的重度COPD患者中减少急性加重效果更明显。
核心结论
- PDE4抑制可降低痰液嗜酸性粒细胞较高COPD患者的痰液嗜酸性粒细胞,支持PDE4抑制剂对嗜酸性炎症的作用。
主要发现
- PDE4抑制可降低痰液嗜酸性粒细胞较高COPD患者的痰液嗜酸性粒细胞。
- 口服PDE4抑制剂罗氟司特在血嗜酸性粒细胞较高的重度COPD患者中减少急性加重效果更明显。
- 血与痰液嗜酸性粒细胞的相关性在部分研究中可见,但并非所有研究均能显示。
- 痰液样本质量差异,尤其在多中心研究中,会影响显示血嗜酸性粒细胞计数关系的能力。
局限性
- 痰液样本质量差异,尤其在多中心研究中,会影响显示血嗜酸性粒细胞计数关系的能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PDE4 inhibition reduces sputum eosinophils in those COPD patients with higher eosinophil counts. This evidence supports an effect of PDE4 inhibitors on eosinophilic inflammation. https://bit.ly/3airXw7 Patients with COPD who have higher eosinophil numbers in the airways and peripheral blood demonstrate a greater clinical response to inhaled corticosteroids (ICS) [1–3]. Furthermore, the effect of the oral phosphodiesterase-4 (PDE4) inhibitor roflumilast on exacerbations in severe COPD patients with chronic bronchitis, who are treated with ICS and long-acting bronchodilators, also appears to be greater at higher blood eosinophil counts [4]. The mechanisms responsible for these differential drug effects remain to be defined, but may relate to increased type-2 inflammation and/or decreased presence of colonising airway bacteria in COPD patients with more eosinophils [5, 6], leading to different responses to anti-inflammatory drugs. An association between blood and sputum eosinophils has been observed in some, but not all studies [7–12]. Accurate sputum eosinophil count measurement requires good quality samples to make cytospins where eosinophils can be clearly counted; variable quality of sputum samples, particularly in multicentre studies, will affect the ability to show a relationship with blood eosinophil counts.
引用
- Singh D, Watz H, Beeh KM, et al. COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition. Eur Respir J. 2020. PMID: 32341106. doi:10.1183/13993003.00237-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。